Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Teduglutide (Gattex) Peptide
GLP-2 analog for short bowel syndrome dependent on parenteral support.
What is Teduglutide (Gattex)?
Teduglutide (Gattex) is a glp-2 analog · gastrointestinal peptide studied for short bowel syndrome with intestinal failure and reduction of parenteral nutrition dependence. Below is an educational overview of Teduglutide (Gattex) peptide benefits, mechanism, common research protocols, dosage references, and known side effects.
Plain-Language Label Highlights
Brand names: Gattex, Revestive
Short bowel syndrome in adults and children requiring IV nutrition support.
A daily injection that helps the remaining intestine grow taller villi and absorb more nutrients, reducing IV feeding needs.
- •Abdominal pain
- •Nausea
- •Stoma complications (in patients with stomas)
- •Headache
- •Fluid overload
- •Acceleration of cancer growth (colorectal polyps require surveillance colonoscopy)
- •Intestinal obstruction
- •Gallbladder, biliary, and pancreatic disease
- •Fluid overload
- •Active GI cancer
- •Suspected colorectal polyps without surveillance
- •Hypersensitivity to teduglutide
Educational summary of the FDA prescribing information. Not a substitute for the full label or medical advice. Always discuss with a licensed prescriber.
Teduglutide (Gattex) Mechanism of Action
Recombinant analog of glucagon-like peptide-2 with alanine→glycine substitution at position 2, resisting DPP-IV degradation; promotes intestinal mucosal growth, villus height, and absorptive capacity.
Teduglutide (Gattex) Research Areas & Benefits
Teduglutide (Gattex) Dosage & Common Research Protocols
0.05 mg/kg subcutaneously once daily.
Protocols summarized for educational reference from published research. Not dosing guidance.
Teduglutide (Gattex) Studies & Cited Research
STEPS trial
Reduced parenteral support volume in SBS patients vs placebo.
Why we trust this source: Source not yet matched to our reputable list. Treat as background information only.
Citations are linked to PubMed, Google Scholar, and Crossref searches so you can verify the source independently. All references are reviewed during our editorial passes (last reviewed June 1, 2026).
Teduglutide (Gattex) Side Effects & Safety Considerations
- •FDA-approved.
- •Colorectal polyp surveillance required.
- •Risk of intestinal obstruction and biliary/pancreatic disease.
Explore more peptides
Educational Information Only — Not Medical Advice
All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.
Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.
Ask the Library
Ask anything about peptides — answers come from our curated reference library with citations.